JPWO2020247496A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020247496A5 JPWO2020247496A5 JP2021572048A JP2021572048A JPWO2020247496A5 JP WO2020247496 A5 JPWO2020247496 A5 JP WO2020247496A5 JP 2021572048 A JP2021572048 A JP 2021572048A JP 2021572048 A JP2021572048 A JP 2021572048A JP WO2020247496 A5 JPWO2020247496 A5 JP WO2020247496A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pharmaceutical composition
- group
- pharmaceutically acceptable
- solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 50
- 239000008194 pharmaceutical composition Substances 0.000 claims 36
- 150000003839 salts Chemical class 0.000 claims 24
- 239000012453 solvate Substances 0.000 claims 24
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 20
- 150000001875 compounds Chemical group 0.000 claims 19
- 239000002246 antineoplastic agent Substances 0.000 claims 15
- 229940127089 cytotoxic agent Drugs 0.000 claims 15
- 229910052736 halogen Inorganic materials 0.000 claims 15
- 150000002367 halogens Chemical class 0.000 claims 15
- 229910052739 hydrogen Inorganic materials 0.000 claims 14
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 12
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims 12
- 229910052799 carbon Inorganic materials 0.000 claims 12
- 239000003814 drug Substances 0.000 claims 11
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 10
- 229940124597 therapeutic agent Drugs 0.000 claims 10
- 125000003545 alkoxy group Chemical group 0.000 claims 9
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims 8
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 8
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 8
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims 8
- 125000005113 hydroxyalkoxy group Chemical group 0.000 claims 8
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 7
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 7
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 7
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 7
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 125000001424 substituent group Chemical group 0.000 claims 6
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 230000005855 radiation Effects 0.000 claims 5
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 4
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 4
- 229940127272 CD73 inhibitor Drugs 0.000 claims 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 4
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 4
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 4
- 239000005557 antagonist Substances 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 4
- 125000003003 spiro group Chemical group 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 2
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims 2
- -1 B7 family member Proteins 0.000 claims 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 2
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims 2
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims 2
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 2
- 102000017578 LAG3 Human genes 0.000 claims 2
- 101150030213 Lag3 gene Proteins 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 229930012538 Paclitaxel Natural products 0.000 claims 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 2
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims 2
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 229940045799 anthracyclines and related substance Drugs 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 2
- 229960004562 carboplatin Drugs 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 229960004316 cisplatin Drugs 0.000 claims 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 2
- 229960004679 doxorubicin Drugs 0.000 claims 2
- 230000002519 immonomodulatory effect Effects 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 229960001756 oxaliplatin Drugs 0.000 claims 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 2
- 229960001592 paclitaxel Drugs 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 229910052697 platinum Inorganic materials 0.000 claims 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 1
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000006332 Choriocarcinoma Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000031481 Pathologic Constriction Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 208000033133 Testicular seminomatous germ cell tumor Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 229960005305 adenosine Drugs 0.000 claims 1
- 210000004100 adrenal gland Anatomy 0.000 claims 1
- 208000002029 allergic contact dermatitis Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 210000000709 aorta Anatomy 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 229960003852 atezolizumab Drugs 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 229950002916 avelumab Drugs 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 210000002808 connective tissue Anatomy 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 229950009791 durvalumab Drugs 0.000 claims 1
- 230000008482 dysregulation Effects 0.000 claims 1
- 230000002357 endometrial effect Effects 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 229960003301 nivolumab Drugs 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229960002621 pembrolizumab Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 208000037804 stenosis Diseases 0.000 claims 1
- 230000036262 stenosis Effects 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 208000024662 testicular seminoma Diseases 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 206010044412 transitional cell carcinoma Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962857148P | 2019-06-04 | 2019-06-04 | |
| US62/857,148 | 2019-06-04 | ||
| PCT/US2020/035920 WO2020247496A1 (en) | 2019-06-04 | 2020-06-03 | 2,3,5-trisubstituted pyrazolo[1,5-a]pyrimidine compounds |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022535120A JP2022535120A (ja) | 2022-08-04 |
| JPWO2020247496A5 true JPWO2020247496A5 (https=) | 2023-06-13 |
| JP2022535120A5 JP2022535120A5 (https=) | 2023-06-13 |
| JP7665534B2 JP7665534B2 (ja) | 2025-04-21 |
Family
ID=73652950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021572048A Active JP7665534B2 (ja) | 2019-06-04 | 2020-06-03 | ２，３，５－三置換ピラゾロ［１，５－ａ］ピリミジン化合物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12410170B2 (https=) |
| EP (1) | EP3980010A4 (https=) |
| JP (1) | JP7665534B2 (https=) |
| KR (1) | KR20220047247A (https=) |
| CN (1) | CN114206332B (https=) |
| AR (1) | AR119088A1 (https=) |
| AU (1) | AU2020288610A1 (https=) |
| CA (1) | CA3142712A1 (https=) |
| TW (1) | TWI857071B (https=) |
| UY (1) | UY38742A (https=) |
| WO (1) | WO2020247496A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112022024221A2 (pt) | 2020-06-02 | 2022-12-20 | Arcus Biosciences Inc | Anticorpos para tigit |
| WO2022226052A1 (en) * | 2021-04-20 | 2022-10-27 | The Regents Of The University Of Michigan | Pi3k inhibitors, nanoformulations, and uses thereof |
| CN117295741A (zh) | 2021-05-21 | 2023-12-26 | 艾库斯生物科学有限公司 | Axl化合物 |
| JP2024521712A (ja) | 2021-05-21 | 2024-06-04 | アーカス バイオサイエンシーズ，インコーポレーテッド | Ａｘｌ阻害化合物 |
| WO2023077046A1 (en) | 2021-10-29 | 2023-05-04 | Arcus Biosciences, Inc. | Inhibitors of hif-2alpha and methods of use thereof |
| CN119072476A (zh) * | 2022-03-02 | 2024-12-03 | 上海海雁医药科技有限公司 | 六元芳环并吡咯酮衍生物、其药物组合物及应用 |
| CA3256561A1 (en) | 2022-05-02 | 2023-11-09 | Arcus Biosciences, Inc. | Anti-tigit antibodies and their uses |
| EP4554680A1 (en) | 2022-07-15 | 2025-05-21 | Arcus Biosciences, Inc. | Inhibitors of hpk1 and methods of use thereof |
| US20260028336A1 (en) | 2022-07-20 | 2026-01-29 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| WO2024046454A1 (zh) * | 2022-09-01 | 2024-03-07 | 上海海雁医药科技有限公司 | 杂芳基取代的吡啶并吡咯酮衍生物、其药物组合物及应用 |
| CN119768155A (zh) | 2022-09-14 | 2025-04-04 | 艾库斯生物科学有限公司 | 依曲地南的分散体 |
| WO2024081385A1 (en) | 2022-10-14 | 2024-04-18 | Arcus Biosciences, Inc. | Hpk1 inhibitors and methods of use thereof |
| EP4604920A1 (en) | 2022-10-20 | 2025-08-27 | Arcus Biosciences, Inc. | Lyophilized formulations of cd73 compounds |
| EP4705292A1 (en) | 2023-05-05 | 2026-03-11 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| US20250011318A1 (en) | 2023-05-25 | 2025-01-09 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| WO2025076299A1 (en) | 2023-10-06 | 2025-04-10 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| WO2025146216A1 (zh) * | 2024-01-05 | 2025-07-10 | 成都赜灵生物医药科技有限公司 | 六并五氮杂环酰胺类化合物及其用途 |
| WO2025193759A1 (en) | 2024-03-12 | 2025-09-18 | Gilead Sciences, Inc. | Solid forms of an azolopyrimidine compound |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0402735D0 (sv) | 2004-11-09 | 2004-11-09 | Astrazeneca Ab | Novel compounds |
| AU2007206860A1 (en) | 2006-01-23 | 2007-07-26 | Laboratoires Serono S.A. | Thiazole derivatives and use thereof |
| JP5336375B2 (ja) | 2006-08-30 | 2013-11-06 | セルゾーム リミテッド | キナーゼ阻害剤としてのトリアゾール誘導体 |
| US20080234262A1 (en) | 2007-03-21 | 2008-09-25 | Wyeth | Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors |
| AR067326A1 (es) * | 2007-05-11 | 2009-10-07 | Novartis Ag | Imidazopiridinas y pirrolo -pirimidinas sustituidas como inhibidores de cinasa de lipido |
| MX2010005700A (es) | 2007-11-27 | 2010-06-11 | Cellzome Ltd | Amino triazoles como inhibidores pi3k. |
| GB0812309D0 (en) | 2008-07-03 | 2008-08-13 | Ucb Pharma Sa | Therapeutic agents |
| WO2010039740A1 (en) | 2008-09-30 | 2010-04-08 | Exelixis, Inc. | PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα AND MTOR |
| US8476431B2 (en) | 2008-11-03 | 2013-07-02 | Itellikine LLC | Benzoxazole kinase inhibitors and methods of use |
| PE20121148A1 (es) | 2009-08-17 | 2012-09-07 | Intellikine Llc | Compuestos heterociclicos y usos de los mismos |
| AU2010341573B2 (en) | 2009-12-22 | 2016-10-13 | Vertex Pharmaceuticals Incorporated | Isoindolinone inhibitors of phosphatidylinositol 3-kinase |
| US9737521B2 (en) | 2012-11-08 | 2017-08-22 | Rhizen Pharmaceuticals Sa | Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor |
| SG10201802061TA (en) | 2013-09-25 | 2018-05-30 | Vertex Pharma | A selective inhibitor of phosphatidylinositol 3-kinase-gamma |
| MX2021012208A (es) | 2013-10-04 | 2023-01-19 | Infinity Pharmaceuticals Inc | Compuestos heterocíclicos y usos de los mismos. |
| NZ724368A (en) * | 2014-03-19 | 2023-07-28 | Infinity Pharmaceuticals Inc | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
| KR20160145780A (ko) | 2014-04-24 | 2016-12-20 | 노파르티스 아게 | 포스파티딜이노시톨 3-키나제 억제제로서의 아미노 피리딘 유도체 |
| EP3134397A1 (en) | 2014-04-24 | 2017-03-01 | Novartis AG | Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors |
| KR20160141856A (ko) | 2014-04-24 | 2016-12-09 | 노파르티스 아게 | 포스파티딜이노시톨 3-키나제 억제제로서의 피라진 유도체 |
| US10786504B2 (en) | 2014-09-03 | 2020-09-29 | Rhizen Pharmaceuticals Sa | Method of treatment and compositions comprising a dual PI3K delta-gamma kinase inhibitor and a corticosteroid |
| US10023576B2 (en) | 2014-10-22 | 2018-07-17 | Bristol-Myers Squibb Company | Heteroaryl substituted pyrrolotriazine amine compounds as PI3K inhibitors |
| US9988401B2 (en) | 2015-05-11 | 2018-06-05 | Incyte Corporation | Crystalline forms of a PI3K inhibitor |
| EP4585268A3 (en) | 2015-09-14 | 2025-10-15 | Twelve Therapeutics, Inc. | Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same |
| RS63359B1 (sr) | 2015-11-06 | 2022-07-29 | Incyte Corp | Heterociklična jedinjenja kao inhibitori pi3k-gama |
| AR107840A1 (es) | 2016-03-10 | 2018-06-13 | Astrazeneca Ab | INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASA g |
| US10759806B2 (en) | 2016-03-17 | 2020-09-01 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors |
| WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| WO2017223414A1 (en) | 2016-06-24 | 2017-12-28 | Incyte Corporation | HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS |
| US10961236B2 (en) | 2016-09-22 | 2021-03-30 | Astrazeneca Ab | (S)-2-(1-cyclopropylethyl)-5-(4-methyl-2-((6-(2-oxopyrrolidin-1-yl)pyridin-2-yl)amino) thiazol-5-yl)-7-(methylsulfonyl)isoindolin-1-one as a phosphatidylinositol 3-kinase inhibitor |
| CN108017641B (zh) | 2016-11-02 | 2021-01-05 | 深圳铂立健医药有限公司 | 吡唑并嘧啶化合物作为pi3k抑制剂及其应用 |
| KR20240152947A (ko) | 2017-10-18 | 2024-10-22 | 인사이트 코포레이션 | Pi3k-감마 저해제로서의 3차 하이드록시기로 치환된 축합된 이미다졸 유도체 |
-
2020
- 2020-06-03 KR KR1020227000091A patent/KR20220047247A/ko not_active Ceased
- 2020-06-03 JP JP2021572048A patent/JP7665534B2/ja active Active
- 2020-06-03 AU AU2020288610A patent/AU2020288610A1/en not_active Abandoned
- 2020-06-03 CA CA3142712A patent/CA3142712A1/en active Pending
- 2020-06-03 CN CN202080053447.9A patent/CN114206332B/zh active Active
- 2020-06-03 WO PCT/US2020/035920 patent/WO2020247496A1/en not_active Ceased
- 2020-06-03 EP EP20818646.0A patent/EP3980010A4/en active Pending
- 2020-06-03 US US17/615,550 patent/US12410170B2/en active Active
- 2020-06-04 UY UY0001038742A patent/UY38742A/es not_active Application Discontinuation
- 2020-06-04 TW TW109118850A patent/TWI857071B/zh active
- 2020-06-04 AR ARP200101579A patent/AR119088A1/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020247496A5 (https=) | ||
| JP2020111618A5 (https=) | ||
| IL295569A (en) | Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2alpha | |
| JP2021516237A5 (https=) | ||
| JP2019529500A5 (https=) | ||
| JPWO2021188769A5 (https=) | ||
| AU2018282363B2 (en) | Compounds and methods of use | |
| JP2025023997A (ja) | Ｆａｋ阻害剤およびその併用薬物 | |
| RU2344123C9 (ru) | 3,4-дизамещенные циклобутен-1,2-дионы как лиганды схс-хемокинового рецептора | |
| JP5881705B2 (ja) | Ｎａｍｐｔの阻害のための新規化合物及び組成物 | |
| JP2019501223A5 (https=) | ||
| JPWO2022246179A5 (https=) | ||
| JP2017525753A5 (https=) | ||
| AU2010290199B2 (en) | Kinase inhibitors, prodrug forms thereof and their use in therapy | |
| RU2012151012A (ru) | Циклопропиловые дикарбоксамиды и аналоги, обладающие противораковым и антипролиферативным действием | |
| JPWO2018204661A5 (https=) | ||
| JP2018519245A5 (https=) | ||
| RU2016149812A (ru) | Иммунорегулирующие средства | |
| JP2016503414A5 (https=) | ||
| JP2013522292A5 (https=) | ||
| RU2000129508A (ru) | Сульфонамид-содержащие соединения индола | |
| JP2010522765A5 (https=) | ||
| JPWO2021081212A5 (https=) | ||
| JP2016033166A (ja) | Ａｒｒｙ−３８０の多形体、選択的ｅｒｂｂ２（ｈｅｒ２）阻害剤、およびそれらを含有する薬学的組成物 | |
| JPWO2020102646A5 (https=) |